Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

5.940 USD +0.220 (+3.85%)
Official Closing Price Updated: 7:54 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Adaptimmune Ther Ads

< Previous 1 2 3 4 5 6 7 Next >
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
From GlobeNewswire News Releases
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
From GlobeNewswire News Releases
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
From GlobeNewswire News Releases
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
From GlobeNewswire News Releases
Adaptimmune Reports Q3 Financial Results and Business Update
From GlobeNewswire News Releases
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
From GlobeNewswire News Releases
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
From GlobeNewswire News Releases
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
From InvestorBrandNetwork
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation
NetworkNewsWire Editorial Coverage 
From PR Newswire
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
From GlobeNewswire News Releases
Adaptimmune Reports Q2 Financial Results and Business Update
From GlobeNewswire News Releases
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
From GlobeNewswire News Releases
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
From GlobeNewswire News Releases
NetworkNewsBreaks – Adaptimmune Therapeutics plc (NASDAQ: ADAP) Closes $259.3M Follow-On
From InvestorBrandNetwork
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?
InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB. 
From PR Newswire
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
From GlobeNewswire News Releases
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?
InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO. 
From PR Newswire
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
From GlobeNewswire News Releases
Adaptimmune Reports Q1 Financial Results
From GlobeNewswire News Releases
Thinking about buying stock in Adaptimmune Therapeutics, Upwork, Eldorado Resorts, Co-Diagnostics, or Delta Air Lines?
InvestorsObserver issues critical PriceWatch Alerts for ADAP, UPWK, ERI, CODX, and DAL. 
From PR Newswire
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
From GlobeNewswire News Releases
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
From GlobeNewswire News Releases
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
From GlobeNewswire News Releases
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
From GlobeNewswire News Releases
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
From GlobeNewswire News Releases
NetworkNewsBreaks – Adaptimmune Therapeutics plc (NASDAQ: ADAP) Secures $84M in Underwritten Public Offering
From InvestorBrandNetwork
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.